Article
Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.
European journal of nuclear medicine and molecular imaging - 1 May 2018
Lv Zhilei, Fan Jinshuo, Xu Juanjuan, Wu Feng, Huang Qi, Guo Mengfei, Liao Tingting, Liu Shuqing, Lan Xiaoli, Liao Shanshan, Geng Wei, Jin Yang
Abstract excerpt
PURPOSE: Epidermal growth factor receptor (EGFR) mutations and the anaplastic lymphoma kinase (ALK) rearrangement are the two most common druggable targets in non-small cell lung cancer (NSCLC). However, genetic testing is sometimes unavailable. Previous studies regarding the predictive role of 18F-FDG PET/CT for EGFR mutations in NSCLC patients are conflicting. We investigated whether or not 18F-FDG PET could be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.